Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $67,624 | $219,360 | $443,005 | $1,876,634 |
| - Cash | $1,191 | $4,706 | $6,504 | $16,498 |
| + Debt | $74 | $151 | $229 | $78 |
| Enterprise Value | $66,506 | $214,805 | $436,731 | $1,860,215 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12,050 | -$11,457 | -$19,469 | -$10,776 |
| % Margin | – | – | – | – |
| Net Income | -$11,850 | -$11,122 | -$27,424 | -$11,428 |
| % Margin | – | – | – | – |
| EPS Diluted | -96.75 | -212 | -42.5 | -373 |
| % Growth | 54.4% | -398.8% | 88.6% | – |
| Operating Cash Flow | -$11,245 | -$8,063 | -$9,605 | -$8,717 |
| Capital Expenditures | -$3 | -$3 | $0 | $0 |
| Free Cash Flow | -$11,248 | -$8,066 | -$9,605 | -$8,717 |